Related references
Note: Only part of the references are listed.Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals
Jason Ho et al.
AIDS (2011)
Narcolepsy Onset Is Seasonal and Increased following the 2009 H1N1 Pandemic in China
Fang Han et al.
ANNALS OF NEUROLOGY (2011)
Immunogenicity, Boostability, and Sustainability of the Immune Response after Vaccination against Influenza A Virus (H1N1) 2009 in a Healthy Population
Elisabeth Huijskens et al.
CLINICAL AND VACCINE IMMUNOLOGY (2011)
Effect on Cellular and Humoral Immune Responses of the AS03 Adjuvant System in an A/H1N1/2009 Influenza Virus Vaccine Administered to Adults during Two Randomized Controlled Trials
Francois Roman et al.
CLINICAL AND VACCINE IMMUNOLOGY (2011)
Effectiveness of an Adjuvanted Monovalent Vaccine Against the 2009 Pandemic Strain of Influenza A(H1N1)v, in Stockholm County, Sweden
Ake Ortqvist et al.
CLINICAL INFECTIOUS DISEASES (2011)
2009 Pandemic Influenza A (H1N1) Deaths among Children-United States, 2009-2010
Chad M. Cox et al.
CLINICAL INFECTIOUS DISEASES (2011)
Influenza viral neuraminidase: the forgotten antigen
Bert E. Johansson et al.
EXPERT REVIEW OF VACCINES (2011)
H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses
Philippe Moris et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2011)
Age-Specific Effectiveness of an Oil-in-Water Adjuvanted Pandemic (H1N1) 2009 Vaccine Against Confirmed Infection in High Risk Groups in England
Nick Andrews et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Rapid Immunization Against H5N1: A Randomized Trial Evaluating Homologous and Cross-Reactive Immune Responses to AS03A-Adjuvanted Vaccination in Adults
Benjamin Lasko et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Dose-Sparing H5N1 A/Indonesia/05/2005 Pre-pandemic Influenza Vaccine in Adults and Elderly Adults: A Phase III, Placebo-Controlled, Randomized Study
Joanne M. Langley et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial
Karl G. Nicholson et al.
LANCET INFECTIOUS DISEASES (2011)
Field Effectiveness of Pandemic and 2009-2010 Seasonal Vaccines against 2009-2010 A(H1N1) Influenza: Estimations from Surveillance Data in France
Camille Pelat et al.
PLOS ONE (2011)
Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets
Benoit Baras et al.
VACCINE (2011)
Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months
George Risi et al.
VACCINE (2011)
Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity
Sandra Morel et al.
VACCINE (2011)
Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naive ferrets
Benoit Baras et al.
VACCINE (2011)
Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents
J. Garcia-Sicilia et al.
VACCINE (2011)
Immune responses to influenza virus infection
J. H. C. M. Kreijtz et al.
VIRUS RESEARCH (2011)
Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009-2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study
Marta Valenciano et al.
PLOS MEDICINE (2011)
Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009
Danuta M. Skowronski et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
A Heterologous MF59-Adjuvanted H5N1 Prepandemic Influenza Booster Vaccine Induces a Robust, Cross-Reactive Immune Response in Adults and the Elderly
Elena Fragapane et al.
CLINICAL AND VACCINE IMMUNOLOGY (2010)
AS03A-Adjuvanted Influenza A (H1N1) 2009 Vaccine for Adults up to 85 Years of Age
Francois Roman et al.
CLINICAL INFECTIOUS DISEASES (2010)
Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine
Woolf T. Walker et al.
EXPERT REVIEW OF VACCINES (2010)
Immunogenicity and safety of a novel AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan
Hideyuki Ikematsu et al.
HUMAN VACCINES (2010)
Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination
M. Juliana McElrath et al.
IMMUNITY (2010)
Protective effect of single-dose adjuvanted pandemic influenza vaccine in children
P. G. Van Buynder et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2010)
CDC Advisory Committee Recommends Nearly Universal Influenza Vaccination
Bridget M. Kuehn
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Safety and Cross-Reactive Immunogenicity of Candidate AS03-Adjuvanted Prepandemic H5N1 Influenza Vaccines: A Randomized Controlled Phase 1/2 Trial in Adults
Joanne M. Langley et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study
Elizabeth Miller et al.
LANCET (2010)
Vaccines with MF59 Adjuvant Expand the Antibody Repertoire to Target Protective Sites of Pandemic Avian H5N1 Influenza Virus
Surender Khurana et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellon, Spain. A test-negative, hospital-based, case-control study
Joan Puig-Barbera et al.
VACCINE (2010)
An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers
Abdullah S. Madhun et al.
VACCINE (2010)
Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trial
Francois Roman et al.
VACCINE (2010)
Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study
Isabel Leroux-Roels et al.
VACCINE (2010)
Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months
Alfonso Carmona et al.
VACCINE (2010)
Economic Appraisal of Ontario's Universal Influenza Immunization Program: A Cost-Utility Analysis
Beate Sander et al.
PLOS MEDICINE (2010)
Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study
Claire S. Waddington et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Squalene: A natural triterpene for use in disease management and therapy
L. Harivardhan Reddy et al.
ADVANCED DRUG DELIVERY REVIEWS (2009)
Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway
R. Do et al.
CLINICAL GENETICS (2009)
Biological and Pharmacological Activities of Squalene and Related Compounds: Potential Uses in Cosmetic Dermatology
Zih-Rou Huang et al.
MOLECULES (2009)
Response to a Monovalent 2009 Influenza A (H1N1) Vaccine.
Michael E. Greenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine: A phase III study in a large population of Asian adults
Daniel Wai-Sing Chu et al.
VACCINE (2009)
Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults
Tino F. Schwarz et al.
VACCINE (2009)
MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database
Michele Pellegrini et al.
VACCINE (2009)
Vitamin E ingestion improves several immune functions in elderly men and women
Monica De la Fuente et al.
FREE RADICAL RESEARCH (2008)
Age-associated changes in immune and inflammatory responses: impact of vitamin E intervention
Dayong Wu et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2008)
A clinical trial of a whole-virus H5N1 vaccine derived from cell culture
Hartmut J. Ehrlich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine
Isabel Leroux-Roels et al.
PLOS ONE (2008)
Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine
Benoit Baras et al.
PLOS ONE (2008)
Correlates of protection: Novel generations of influenza vaccines
Guus F. Rimmelzwaan et al.
VACCINE (2008)
Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial
Hans C. Rumke et al.
VACCINE (2008)
Modulation of signal transduction by vitamin E
Jean-Marc Zingg
MOLECULAR ASPECTS OF MEDICINE (2007)
Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine:: a randomised controlled trial
Isabel Leroux-Roels et al.
LANCET (2007)
Vitamin E, antioxidant and nothing more
Maret G. Traber et al.
FREE RADICAL BIOLOGY AND MEDICINE (2007)
NF-κB and the immune response
M. S. Hayden et al.
ONCOGENE (2006)
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine:: phase I randomised trial
Jean-Louis Bresson et al.
LANCET (2006)
Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine
JJ Treanor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants
Y Li et al.
JOURNAL OF VIROLOGY (2006)
CD4(+) T-cell memory: generation and multi-faceted roles for CD4(+) T cells in protective immunity to influenza
Susan L. Swain et al.
IMMUNOLOGICAL REVIEWS (2006)
Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: A potential priming strategy
I Stephenson et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Influenza a vaccine based on the extracellular domain of M2: Weak protection mediated via antibody-dependent NK cell activity
A Jegerlehner et al.
JOURNAL OF IMMUNOLOGY (2004)
Regulation of gene expression by α-tocopherol
A Azzi et al.
BIOLOGICAL CHEMISTRY (2004)
Immunogenicity and protective efficacy of influenza vaccination
C Hannoun et al.
VIRUS RESEARCH (2004)
Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-γ
PF Sun et al.
JOURNAL OF IMMUNOLOGY (2003)
Updating the accounts: global mortality of the 1918-1920 Spanish influenza pandemic
NPAS Johnson et al.
BULLETIN OF THE HISTORY OF MEDICINE (2002)
Share Paper
